15072886

Source:http://linkedlifedata.com/resource/pubmed/id/15072886

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0025266, umls-concept:C0036043, umls-concept:C0087111, umls-concept:C0754659, umls-concept:C1704272
pubmed:issue	4
pubmed:dateCreated	2004-4-9
pubmed:abstractText	To assess the long-term safety and efficacy of dutasteride, a dual type 1 and type 2 5-alpha-reductase inhibitor, in the treatment of symptomatic benign prostatic hyperplasia and associated lower urinary tract symptoms.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/15072886-15643232
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0366151
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/5-alpha Reductase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Azasteroids, http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Isoenzymes, http://linkedlifedata.com/resource/pubmed/chemical/Placebos, http://linkedlifedata.com/resource/pubmed/chemical/Prostate-Specific Antigen, http://linkedlifedata.com/resource/pubmed/chemical/dutasteride
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	1527-9995
pubmed:author	pubmed-author:FenterTomT, pubmed-author:FreedmanSheldonS, pubmed-author:GittlemanMarcM, pubmed-author:MarksLeonard SLS, pubmed-author:MorrillBetsyB, pubmed-author:RoehrbornClaus GCG, pubmed-author:TuttleJohnJ, pubmed-author:WolfordEric TET
pubmed:issnType	Electronic
pubmed:volume	63
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	709-15
pubmed:dateRevised	2010-11-18
pubmed:meshHeading	pubmed-meshheading:15072886-5-alpha Reductase Inhibitors, pubmed-meshheading:15072886-Aged, pubmed-meshheading:15072886-Azasteroids, pubmed-meshheading:15072886-Double-Blind Method, pubmed-meshheading:15072886-Ejaculation, pubmed-meshheading:15072886-Enzyme Inhibitors, pubmed-meshheading:15072886-Erectile Dysfunction, pubmed-meshheading:15072886-Gynecomastia, pubmed-meshheading:15072886-Humans, pubmed-meshheading:15072886-Isoenzymes, pubmed-meshheading:15072886-Longitudinal Studies, pubmed-meshheading:15072886-Male, pubmed-meshheading:15072886-Middle Aged, pubmed-meshheading:15072886-Placebos, pubmed-meshheading:15072886-Prostate, pubmed-meshheading:15072886-Prostate-Specific Antigen, pubmed-meshheading:15072886-Prostatic Hyperplasia, pubmed-meshheading:15072886-Sexual Dysfunctions, Psychological, pubmed-meshheading:15072886-Treatment Outcome, pubmed-meshheading:15072886-Urodynamics
pubmed:year	2004
pubmed:articleTitle	Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.
pubmed:affiliation	Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-9110, USA.
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study